Vermillion company Aspira Labs announced the inclusion of the OVA1 /"Multivariate Index Assay" in The American College of Obstetricians and Gynecologists Practice Bulletin Number 174, dated November 2016. Practice Bulletins summarize current information on techniques and clinical management issues for the practice of obstetrics and gynecology. The new guidelines now recommend that all obstetricians and gynecologists, in evaluating women with adnexal masses when the mass does not fulfill Level A criteria of a low risk transvaginal ultrasound, should use risk assessment tools such as OVA1 as listed in the bulletin. Based on this, OVA1 is the only recommended Level B tool with FDA clearance for use in assessing ovarian cancer risk in adnexal masses.